Carcinoma Ex Pleomorphic Adenoma of Salivary Glands, Pleomorphic Adenoma of Salivary Glands
Conditions
Keywords
Cancer stem cells, CD24-Gold Nanocomposite, CD24, Gold nanoparticles, Sensitivity, Specificity
Brief summary
Nano-based diagnostic tool can provide promising highly sensitive, specific biomarker for early detection and treatment of salivary gland tumours compared to non-conjugated biomarkers and in turn improves patient prognosis and outcome.
Detailed description
Cancer stem cells form a small subset of highly tumorigenic cells within the bulk of the tumours which mainly responsible for initiation, invasion, rapid growth, metastasis and therapeutic resistance in different types of human cancers. Nowadays, nanotechnology has increasing attention in multi-disciplinary research fields. Conjugated gold nanoparticles are widely used as biomarkers and bio-delivery vehicles in the medicine as well as early and advanced cancer detection and treatment. The current work aimed to introduce a novel diagnostic and prognostic approach in early detection of cancer stem cells in salivary gland tumours using gold nanoparticles conjugated to CD24 (CD24-Gold Nanocomposite).
Interventions
DIAGNOSTIC_TESTCD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction
new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
DIAGNOSTIC_TESTnon-conjugated CD24 expression using Real-time quantitative polymerase chain reaction
conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
Sponsors
Amina Fouad Farag
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Benign PA of major and minor salivary glands (PA group), * CXPA of major and minor salivary glands (CXPA group). * Border of excision biopsy of mucocele in the lip mucosa of healthy individuals used as normal controls (Control group). * Surgical excision of tumors with no preoperative chemotherapy or radiotherapy. For parotid tumours partial or total parotidectomy, Surgery was performed with or without facial nerve preservation and the later was carried out commonly when the nerve was involved by tumour. For tumours in the other glands, complete surgical excision with the involved gland and the suspicious adjacent structures was performed.
Exclusion criteria
* All epithelial origin salivary gland tumours other than PA and CXPA. * All mesenchymal origin salivary gland tumours. * All inflammatory and cystic lesions of salivary glands. * Metastasis in salivary glands. * Patients received preoperative chemotherapy or radiotherapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic potential of CD24-AuNC (index test) compared to non-conjugated CD24 (reference test) in determination of salivary gland tumours | Done immediately following completion of assessment for eligibility of enrolment in the present study (enrolment took about 6 months) and confirmation of definite diagnosis | we tested the differential expression of CD24-AuNC and non-conjugated CD24 biomarkers in all studied groups in order to identify the most sensitive and specific diagnostic biomarker to be used in detecting salivary gland tumours, |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinicopathological characteristics of the patients and their association with CD24-AuNC (Index test) and non-conjugated CD24 (Reference test) expressions | Done immediately following completion of assessment for eligibility of enrolment in the present study (enrolment took about 6 months) and confirmation of definite diagnosis | We investigated the relationship between both biomarkers' expression and clinicopathological characteristics of PA and CXPA patients such as age, gender, tumor site, tumor size (maximum diameter in mm), histopathological subtype, encapsulation, degree of invasion, facial nerve involvement and lymph node (LN) metastasis that may have direct relation with the tumor prognosis |
| Prognostic significance of CD24-AuNC (index test) compared to non-conjugated CD24 (reference test) in assessing disease progression and/or patient survival | At regular intervals every 3 months for 24-months (follow-up period) | we assessed the disease progression and/or patient survival and examined its association with biomarkers expression |
Countries
Egypt
Outcome results
None listed